MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis

MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis

Targeted therapies for <i>MET</i> exon 14-skipping (<i>METΔe</i><i>x14</i>)-driven lung cancers have generated some promising results but response rates remain below that seen for other kinase-driven cancers. One strategy for improving treatment outcomes is to emp...

Full description

Bibliographic Details
Main Authors: Daniel Lu, Amy Nagelberg, Justine LM Chow, Yankuan T Chen, Quentin Michalchuk, Romel Somwar, William W. Lockwood
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Cancers
Subjects:
lung cancer
targeted therapies
Hepatocyte Growth Factor Receptor
splice-site mutations
RAS
Online Access:https://www.mdpi.com/2072-6694/14/6/1378

Internet

https://www.mdpi.com/2072-6694/14/6/1378

Similar Items